OTCMKTS:ATBPF

Antibe Therapeutics Earnings Date, Estimates, & History

$1.02
+0.05 (+4.91 %)
(As of 09/17/2021 02:57 PM ET)
Add
Compare
Today's Range
$0.97
$1.02
50-Day Range
$0.81
$2.89
52-Week Range
$0.69
$5.88
Volume81,200 shs
Average Volume41,717 shs
Market Capitalization$52.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41

Earnings Summary

Upcoming
Earnings Date
Sep. 20
Estimated

Actual EPS
(Jun. 28)
-$0.11
Missed By -$0.06

Consensus EPS
(Jun. 28)
-$0.05

Last Year's Q3 EPS
(7/24/2020)
-$0.02

Antibe Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Antibe Therapeutics Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Antibe Therapeutics (OTCMKTS:ATBPF) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.47 EPS
Next Year EPS Consensus Estimate: $-0.4 EPS

ATBPF Earnings Information

Antibe Therapeutics last issued its earnings results on June 28th, 2021. The reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.06. The company earned $2.33 million during the quarter, compared to analyst estimates of $8.80 million. Antibe Therapeutics has generated ($0.52) earnings per share over the last year (($0.54) diluted earnings per share). Earnings for Antibe Therapeutics are expected to grow in the coming year, from ($0.47) to ($0.40) per share. Antibe Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, September 20th, 2021 based off prior year's report dates.

Antibe Therapeutics (OTCMKTS:ATBPF) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
9/20/2021
(Estimated)
        
6/28/2021Q4 2021($0.05)($0.11)($0.06)($0.11)$8.80 million$2.33 million
2/12/2021Q3 2021($0.09)($0.12)($0.03)($0.11)$2.00 million$2.14 million
11/13/2020Q2 2021($0.02)($0.02)($0.02)$2.15 million
8/24/2020Q1 2021($0.01)($0.01)($0.01)$0.89 million
7/24/2020Q4 2020($0.02)($0.02)($0.02)$1.75 million
2/24/2020Q3 2020($0.01)($0.01)($0.01)$1.98 million
11/28/2019Q2 2020($0.02)($0.02)($0.02)$1.72 million
8/27/2019Q1 2020($0.01)($0.01)($0.01)$2.07 million
7/16/2019Q4 2019($0.02)($0.02)($0.02)$1.83 million
2/15/2019Q3 2019($0.01)($0.01)($0.01)$1.89 million
11/23/2018Q2 2019($0.01)($0.01)($0.01)$1.58 million
8/29/2018Q1 2019($0.01)($0.01)($0.01)$1.97 million
6/29/2018Q4 2018($0.01)($0.01)($0.01)$1.72 million
2/27/2018Q3 2018($0.01)($0.01)($0.01)$1.76 million
11/28/2017Q2 2018($0.01)($0.01)($0.01)$1.43 million
8/29/2017Q1 2018($0.01)($0.01)($0.01)$1.69 million
7/28/2017Q4 2017($0.02)($0.02)($0.02)$1.73 million
3/1/2017Q3 2017($0.01)($0.01)($0.01)$1.47 million
11/29/2016Q2 2017($0.01)($0.01)($0.01)$1.68 million
8/29/2016Q1 2017($0.01)($0.01)($0.01)$2.04 million
7/29/2016Q4 2016($0.02)($0.02)($0.02)$1.78 million
2/29/2016Q3 2016($0.01)($0.01)($0.01)$1.57 million
11/26/2015Q2 2016($0.01)($0.01)($0.01)
8/21/2015Q1 2016($0.01)($0.01)($0.01)
7/28/2015Q4 2015($0.02)($0.02)($0.02)
2/27/2015Q3 2015($0.02)($0.02)($0.02)
11/28/2014Q2 2015($0.03)($0.03)($0.03)
8/27/2014Q1 2015($0.04)($0.04)($0.04)
7/28/2014Q4 2014($0.03)($0.03)($0.03)
2/27/2014Q3 2014($0.03)($0.03)($0.03)
11/28/2013Q2 2014($0.02)($0.02)($0.02)
8/28/2013Q1 2014($0.01)($0.01)($0.01)
(Earnings results data provided by Zacks Investment Research)
speech bubbles
speech bubbles











Antibe Therapeutics (OTCMKTS:ATBPF) Earnings Frequently Asked Questions

When is Antibe Therapeutics's earnings date?

Antibe Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, September 20th, 2021 based off last year's report dates. Learn more on ATBPF's earnings history

Did Antibe Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Antibe Therapeutics (OTCMKTS:ATBPF) missed the analysts' consensus estimate of ($0.05) by $0.06 with a reported earnings per share (EPS) of ($0.11). Learn more on ATBPF's earnings details

How much revenue does Antibe Therapeutics generate each year?

Antibe Therapeutics (OTCMKTS:ATBPF) has a recorded annual revenue of $7.67 million.

How much profit does Antibe Therapeutics generate each year?

Antibe Therapeutics (OTCMKTS:ATBPF) has a recorded net income of -$19.93 million. ATBPF has generated -$0.52 earnings per share over the last four quarters.

What is Antibe Therapeutics's EPS forecast for next year?

Antibe Therapeutics's earnings are expected to grow from ($0.47) per share to ($0.40) per share in the next year.

This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.